AstraZeneca to sell molecule antibiotics business to Pfizer

AstraZeneca to sell molecule antibiotics business to Pfizer


Pharmaceutical company AstraZeneca plans to sell its molecule antibiotics business to Pfizer in a deal that will be valued in excess of $1.5 billion when rights, royalties and other payments are included. The sale marks a thawing of relations between the British company and New York-based Pfizer after an acrimonious battle to avoid a takeover just a few years ago.



from Biotech News